RAMSEY, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that its subsidiary, ADMA BioCenters, received a two-year certification from the German Health Authorities (GHA). GHA certification allows plasma collected at ADMA BioCenters to be imported into the European Union (EU) and to be purchased by European manufacturers. Most of the plasma imported into the EU or member states originates in the United States.
“We are pleased to have achieved GHA certification in our plasma collection facility. This certification will enable us to offer source plasma in the European Union, expanding our potential customer base. This is a key milestone for ADMA which may allow the company to grow its presence as a global plasma provider,” stated Adam Grossman, President and Chief Executive Officer of ADMA.
“The achievement of attaining GHA certification is a testament to our dedicated team members hard work as well as our robust policies and procedures we have in place,” commented Cyndi Tolman, Vice President of Plasma Services of ADMA BioCenters.
ADMA BioCenters is an FDA licensed facility and is also a member of the International Quality Plasma Program (IQPP) as certified by the Plasma Protein Therapeutics Association (PPTA).
About ADMA BioCenters
ADMA BioCenters, located in Norcross, Georgia, is a wholly-owned subsidiary of ADMA Biologics, Inc. The center is FDA-licensed and GHA certified to operate as a source plasma collection facility.
ADMA BioCenters strictly follow FDA regulations and guidance and enforces cGMP (Good Manufacturing Practices) in its facility as well as being GHA certified. A typical plasma collection center, such as ADMA BioCenters, can collect 30,000 to 50,000 liters of source plasma annually. Plasma collected from ADMA BioCenters that is not used for making RI-002 is sold to customers under an existing supply agreement or in the open “spot” market generating revenues for the company. Additional information may be obtained from the ADMA BioCenters website: www.atlantaplasma.com.
About ADMA Biologics, Inc.
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. ADMA’s mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-compromised for medical reasons. ADMA also operates ADMA Bio Centers, which is an FDA-licensed and GHA certified source plasma collection facility located in Norcross, Georgia, which provides us with a portion of our blood plasma for the manufacture of RI-002. For more information please visit the Company’s website at: www.admabiologics.com
Cautionary Statement Regarding Forward-Looking Information
This press release contains “forward looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “will likely,” “should,” “could,” “would,” “may” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements concerning the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations, potential investigational new product applications, biologics license applications, and commercialization efforts of the Company's product candidate(s). Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks listed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission on March 6, 2013. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent to the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward looking statements or to announce revisions to any of the forward-looking statements.